Proactive Investors - Run By Investors For Investors

IGF Oncology in Phase 1b/2a for its blood cancer treatment at the Mayo Clinic

IGF Oncology CEO Hugh McTavish sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

IGF Oncology is a biotech company developing targeted anti-cancer drugs. Its lead drug, IGF-MTX, targets blood cancer, and is currently in clinical trials at the Mayo Clinic.

View full IGF profile View Profile

IGF Oncology Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use